LIGANDROL - Xt Labs

Ligandrol (LGD-4033), developed by Ligand Pharmaceuticals and later licensed to Viking Pharmaceuticals in 2014, is a second-generation selective androgen receptor modulator (SARM) introduced in 2007. It underwent successful Phase I trials by 2012, showing significant lean body mass increases without hepatotoxicity. In fitness circles, Ligandrol gained traction for its strong anabolic and low androgenic profile, often favored over Ostarine. However, despite low liver strain, it showed marked suppression of testosterone and negative effects on HDL cholesterol.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about LIGANDROL by Xt Labs, consult with your doctor or healthcare professional.